A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and weigh at least 40 kg (about 88 pounds).
- You must have had eczema for at least 12 months.
- Your eczema must be moderate to severe, covering at least 10% of your body and with a certain score on skin assessments.
- You must have tried topical treatments (like steroid creams) and they didn't work well enough or you couldn't tolerate them.
- You cannot have certain other skin conditions, infections, or a history of unstable eczema.
- You cannot have taken certain other eczema treatments like biologic drugs or JAK inhibitors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
This trial tests an investigational drug called AK139, given as an injection, for people with moderate-to-severe atopic dermatitis (eczema). The goal is to reduce itching and clear skin better than current topical treatments.
This study tests a new medication called HXN5003 to see if it is safe and how well it works for people with moderate-to-severe eczema (atopic dermatitis). It may help reduce symptoms like itching and rash.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This study tests an investigational medicine called Tilrekimig for people with moderate-to-severe eczema (atopic dermatitis) that hasn't improved with standard treatments. It aims to see if the medicine can reduce symptoms and improve quality of life.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.